In the News
March 6, 2018
Tinoro, Inc. announces issuance of a second US patent for Non-thermal Cycling for PCR Technology
San Diego, CA, March 6, 2018 - Tinoro, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,909,172 on March 6, 2018. This newly issued patent covers design aspects of a fluid chamber related to non-thermal cycling for Polymerase Chain Reaction (PCR). The proprietary technology covered by the patent has been exclusively licensed by Tinoro from the University of California, San Diego.
Harel Hakakha, President and CEO of Tinoro, commented, "The issuance of a second patent that covers our unique technology further enhances the Company's intellectual property position. Now that both method and design claims have been granted in separate patents - the Company is well positioned to pursue commercial production and licensing opportunities."
Tinoro and UCSD continue to pursue additional method and design claims related to the technology.
March 28, 2017
Tinoro, Inc. announces the addition of Todd Peterson and Jonas Ekblom to its Board of Advisors
San Diego, CA, March 28, 2017 - Tinoro, Inc. announced today that Dr. Todd Peterson and Dr. Jonas Ekblom have agreed to join its Board of Advisors. Their extensive experience with various organizations in the biotechnology instrument space will provide Tinoro with invaluable business-side expertise.
Dr. Peterson has over 25 years experience in industrial research and development in the areas of molecular biology, nucleic acids and genomics product and technology development. His experience encompasses clinical diagnostics, life science research tools, and pharmaceutical discovery technologies and market segments. Dr. Peterson currently serves as CTO of Synthetic Genomics.
Dr. Ekblom has over 20 years of experience in the life science sector. He has managed R&D programs in multiple fields of medical technology and in several therapeutic areas. Most recently, Jonas served as CEO of Bows Pharmaceuticals AG, a Swiss drug delivery company. Prior to that, he held senior management positions at Pharmacia, Biovitrum, Sequenom, and Thermo Fisher Scientific.
October 7, 2016
Tinoro, Inc. announces strategic investment by Analytics Ventures, Inc.
San Diego, CA, October 7, 2016 - Tinoro Inc. announced today that Analytics Ventures, LLC has made a strategic investment in the company to support the development and commercialization efforts for its novel DNA amplification technology.
“We are very excited to welcome Analytics Ventures as a long term investor and strategic partner,” said Harel Hakakha, President and CEO of Tinoro. “This strategic investment provides us with the necessary capital and resources to accelerate the development of our technology. These efforts will enable devices capable of rapid, low-cost tests for point-of-care and remote locations where the use of standard PCR technologies is not feasible. Our target applications include rapid screening for common viruses and bacterial infections in hospitals and elder care facilities, testing along the entire food supply chain to minimize the likelihood of illnesses, and on-site testing for forensics, cruise ships, and remote developing world locals.”
“We are very enthusiastic to become a strategic investor for Tinoro,” said Andreas Roell, Managing Partner of Analytics Ventures. “Tinoro will benefit from our proven operational framework and network of resources. We look forward to working closely with the company to bring this exciting technology to market."
August 9, 2016
Tinoro, Inc. announces issuance of a new US patent for Non-thermal Cycling for PCR Technology
San Diego, CA, August 9, 2016 - Tinoro, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,410,171 on August 9, 2016. This newly issued patent covers methods related to non-thermal cycling for Polymerase Chain Reaction (PCR). The proprietary technology covered by the patent has been exclusively licensed by Tinoro from the University of California, San Diego.
Harel Hakakha, President and CEO of Tinoro, commented, "The issued patent greatly enhances the Company's intellectual property position. We strongly believe that the methods outlined in the patent are truly revolutionary, and will enable game changing devices for remote and point of care locations." He added, "Our IP position will strengthen further as we continue to develop and commercialize this unique technology."
The Company and UCSD continue to prosecute additional patent applications for the technology, which, if issued, would provide additional patent protection for other aspects of this novel system for rapid DNA amplification.
January 5, 2015
Tinoro, Inc. Signs Licensing Agreement with the University of California San Diego
Announcing an agreement to purchase IP technology from UCSD for a novel way to amplify DNA
San Diego, CA, January 5, 2015 -- Tinoro, Inc. announced today that the company has signed an exclusive Licensing Agreement with the University of California San Diego to bring to market a unique system to rapidly amplify DNA.
“This one of a kind technology for amplifying DNA is truly an industry breakthrough,” said Harel Hakakha, President and CEO of Tinoro, Inc. “Its unique features enable the development of inexpensive, handheld DNA amplification devices and associated consumables. The technology eliminates the need to thermally cycle a PCR solution - and as a result, amplified DNA products can be generated in a fraction of the time that's needed using traditional methods."
Dr. Inanc Ortac, principal inventor of the technology commented, “The University is very pleased to be moving this transformative technology to the next stage of development and looks forward to working with Tinoro in the commercialization process.” He added, “UC San Diego is excited about the prospect of eventually advancing this unique system into markets with an unmet need, like hospitals and clinics, where it can improve conditions and safety for patients.”
Tinoro, Inc. provides products, partnerships and services to the worldwide research and clinical markets.